ECO 2026: indirect comparison favours Wegovy pill over Foundayo
On 15 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from a post-hoc indirect treatment comparison …
Post
-
-
Nonprofits join forces to debut marketplace for shelved CGTs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have teamed up to launch an …
-
ECO 2026: tirzepatide shows potential for T1D treatment
During the 2026 European Congress on Obesity (ECO) in Istanbul, a meta-analysis was presented analysing the use of tirzepatide, a …
-
Arna Pharma and Slate Run complete JV for new US company
Arna Pharma and Slate Run Pharmaceuticals have completed a joint venture (JV) to form a speciality pharmaceutical company in the …
-
Biopharma industry endorses Pazdur for FDA commissioner role
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week, …
-
Kyowa Kirin secures FDA approval for Crysvita dosing update
Kyowa Kirin has received approval from the US Food and Drug Administration (FDA) for a dosing update to the prescribing …
-
ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term
On May 13, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase III SURMOUNT-MAINTAIN trial …
-
ECO 2026: ATTAIN-MAINTAIN trial showcases orforglipron’s role in sustained weight loss
On 13 May, at the 33rd European Congress on Obesity in Istanbul, Türkiye, findings from the Phase 3b ATTAIN-MAINTAIN trial …
-
UK health secretary Wes Streeting resigns
UK health secretary Wes Streeting has resigned, citing a ‘loss of faith’ in the Labour party’s leadership under Prime Minister …
-
Regulatory round-up: A month of key FDA approvals for cancer drugs
It has been a big month for the oncology space, underpinned by several US approvals in haematological and solid tumour …
-
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS
AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form …
-
ECO 2026: gut hormone signals differ in T1D with obesity
At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY …
-
Zydus to acquire Assertio in $166m deal
Zydus Lifesciences (Zydus) is set to acquire all outstanding Assertio common shares in a deal valued at around $166.4m, through …
-
Coya Therapeutics secures FDA fast track status for COYA 302
Coya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for COYA 302, an investigational …
-
Pfizer receives EC approval for Hympavzi to treat haemophilia
Pfizer has received the European Commission’s (EC) marketing authorisation for expanding the approved Hympavzi (marstacimab) indication to treat haemophilia A or …
